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Introduction
The αIIbβ3 integrin is expressed on platelets and platelet pre-
cursors, megakaryocytes. Integrin αIIbβ3, when in a resting 
state, does not bind plasma fi  brinogen. However, upon platelet 
stimulation by agonists such as thrombin, intracellular signals 
are generated that change the conformation of αIIbβ3 to an ac-
tive state via “inside-out” signaling (for review see Parise et al., 
2001). Activated αIIbβ3 is competent to bind soluble ligands, 
such as fi  brinogen or von Willebrand factor, which link platelets 
together in aggregates. Although it is known that activation of 
αIIbβ3 requires the integrin cytoplasmic tails (O’Toole et al., 
1994; Hughes et al., 1996; Vinogradova et al., 2004), the role of 
the αIIb tail in this process is not well understood.
Previously, we identifi  ed calcium and integrin binding pro-
tein 1 (CIB1; also known as CIB [Naik et al., 1997] and calmyrin 
[Stabler et al., 1999]), which binds to the integrin αIIb cyto-
plasmic tail. CIB1 is an EF-hand–containing, calcium binding 
protein that interacts with hydrophobic residues within the mem-
brane-proximal region of the αIIb cytoplasmic tail (Naik et al., 
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1997; Shock et al., 1999; Barry et al., 2002; Gentry et al., 2005).   
Although CIB1 is expressed in a variety of tissues including plate-
lets, its potential interaction with other integrin α or β subunits to 
date has not been reported (Naik et al., 1997; Shock et al., 1999; 
Barry et al., 2002). However, CIB1 also interacts with   several 
protein kinases, such as p21-activated kinase 1 (PAK1; Leisner 
et al., 2005) and FAK (Naik and Naik, 2003a).
Because CIB1 is one of a few proteins known to bind di-
rectly to the αIIb cytoplasmic tail, we hypothesized that CIB1 
may modulate platelet αIIbβ3 activation. To determine whether 
CIB1 affects αIIbβ3 activation, we used differentiated mega-
karyocytes from murine bone marrow because megakaryocytes, 
unlike platelets, are amenable to direct genetic manipulation. 
However, like platelets but unlike many cell lines, mature meg  a-
karyocytes express αIIbβ3 and activate this integrin in response 
to agonists (Shiraga et al., 1999; Shattil and Leavitt, 2001; 
Bertoni et al., 2002), making them a suitable model system for 
studying platelet integrin regulation. We provide evidence that 
CIB1 is an inhibitor of agonist-induced αIIbβ3 activation, most 
likely via competition with talin binding to αIIbβ3.
Results and discussion
CIB1 has been shown to interact with the αIIb cytoplasmic 
tail by multiple approaches (Naik et al., 1997; Shock et al., 
1999; Barry et al., 2002; Tsuboi, 2002) with an affi  nity of 
 0.3 μM (Barry et al., 2002). We fi  nd that endogenous CIB1 
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I
n response to agonist stimulation, the αIIbβ3 integrin 
on platelets is converted to an active conformation that 
binds ﬁ  brinogen and mediates platelet aggregation. 
This process contributes to both normal hemostasis and 
thrombosis. Activation of αIIbβ3 is believed to occur in part 
via engagement of the β3 cytoplasmic tail with talin; how-
ever, the role of the αIIb tail and its potential binding part-
ners in regulating αIIbβ3 activation is less clear. We report 
that calcium and integrin binding protein 1 (CIB1), which in-
teracts directly with the αIIb tail, is an endogenous inhibitor 
of αIIbβ3 activation; overexpression of CIB1 in megakaryo-
cytes blocks agonist-induced αIIbβ3 activation, whereas re-
duction of endogenous CIB1 via RNA interference enhances 
activation. CIB1 appears to inhibit integrin activation by 
competing with talin for binding to αIIbβ3, thus providing a 
model for tightly controlled regulation of αIIbβ3 activation.T
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 coimmunoprecipitates  with  αIIbβ3 from both resting and 
 agonist-activated platelets, with an increased apparent associa-
tion in activated platelets (Fig. 1 A), in agreement with the puri-
fi  ed protein studies of Vallar et al. (1999). However, the role of 
CIB1 in regulating αIIbβ3 function has been unclear. To address 
the role of CIB1 in αIIbβ3 activation, a well-characterized mega-
karyocyte model system (Shiraga et al., 1999; Shattil and Leavitt, 
2001; Bertoni et al., 2002) was used. Stimulation of mature mu-
rine mega karyocytes with protease-activated receptor 4 activating 
peptide (PAR4P) signifi  cantly increased fi  brinogen binding over 
basal levels to unstimulated megakaryocytes (agonist-  induced 
binding is shown as percent over basal binding, which was 
subtracted from total binding). The PAR4P-induced fi  brinogen 
binding was completely blocked by an anti-αIIbβ3 function-
blocking mAb, 1B5 (Fig. S1 A, available at http://www.jcb.org/cgi/ 
content/full/jcb.200505131/DC1), in agreement with Shiraga 
et al. (1999), further confi  rming the use of fi  brinogen binding as a 
specifi  c marker of αIIbβ3 activation in megakaryocytes. Fibrino-
gen binding to unstimulated megakaryocytes was not affected by 
either the 1B5 mAb or by divalent cation chelation with EDTA 
(Fig. S1 A), indicating no basal αIIbβ3 activation.
We then asked whether CIB1 affects agonist-induced 
αIIbβ3 activation. Megakaryocytes overexpressing either EGFP 
or CIB1-EGFP were stimulated with a PAR4P, followed by 
three-color fl  ow cytometric analysis to gate on large, live cells 
expressing GFP fl  uorescence (see Materials and methods). 
  Protein overexpression was confi  rmed by Western blotting 
(Fig. 1 B, inset) and by fl  uorescence microscopy (Fig. S1 E). 
We found that CIB1-EGFP completely inhibited agonist-
 induced  fi  brinogen binding compared with either EGFP alone 
or untransduced megakaryocytes (Fig. 1 B) but did not inhibit 
fi  brinogen binding to megakaryocytes exposed to 1 mM MnCl2 
(Fig. S1 C), which directly activates αIIbβ3 independent of 
agonist-induced, inside-out signaling. These data suggest that 
CIB1 negatively regulates agonist-induced αIIbβ3 activation.
In addition to binding the αIIb tail, CIB1 also interacts 
with the serine/threonine kinase PAK1 (Leisner, et al., 2005; 
Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200505131/DC1). Because platelets (Leisner et al., 2005) 
and megakaryocytes (Fig. 1 C) express PAK1, we asked 
whether CIB1 inhibits αIIbβ3 activation via a direct interac-
tion with αIIb or indirectly via PAK1. We therefore overex-
pressed a CIB1 mutant (CIB1 F173A-EGFP) that does not bind 
αIIb (Barry et al., 2002) but retains binding activity to PAK1 
(Fig. S2 A). Previous analysis of this mutant by circular 
  dichroism indicated minimal change of CIB1 structure (Barry 
et al., 2002), and yeast two-hybrid analysis confi  rmed that the 
mutant does not bind mouse αIIb (Fig. S2 B). Although the level 
of CIB1 F173A overexpression relative to endogenous CIB1 
and percent of cells transduced was comparable to that of wild-
type CIB1 (Fig. 1 B [inset] and Fig. S1 E), the CIB1 F173A 
mutant was unable to suppress PAR4P-induced αIIbβ3 activa-
tion (Fig. 1 B). In addition, expression levels of αIIbβ3 and 
basal fi  brinogen binding to unstimulated megakaryocytes were 
Figure 1.  CIB1 coimmunoprecipitation and 
inhibition of agonist-induced ﬁ  brinogen binding 
to megakaryocytes.  (A)  αIIbβ3 coimmuno-
precipitates with CIB1 in washed human plate-
lets. CIB1 was immunoprecipitated from lysates 
of resting or thrombin receptor activating pep-
tide (TRAP)–stimulated human platelets using 
either a control IgY or anti-CIB1 chicken IgY 
antibody. The membrane was probed with an 
anti-αIIb antibody and an anti-CIB1 chicken 
antibody. Whole cell lysates (WCL) indicate 
the position of αIIb. Blot represents three sepa-
rate experiments. (B) Untransduced, EGFP-, 
CIB1-EGFP–, or CIB1 F173A-EGFP–  expressing 
megakaryocytes were tested for agonist-induced 
increases in ﬁ  brinogen binding upon stimula-
tion with 3 mM PAR4P. Data are percent in-
creases in mean ﬂ   uorescence over basal 
binding (i.e., total minus basal binding). 
*, P < 0.001, as compared with all other 
groups. The inset shows expression of CIB1-
EGFP and CIB1 F173A-EGFP fusion proteins 
and endogenous CIB1 in transduced megakar-
yocytes, quantiﬁ  ed by densitometry. Data are 
presented as fold increase over endogenous 
CIB1 expression. (C) Expression of endoge-
nous CIB1 in control and CIB1 siRNA–
  transfected megakaryocytes. The membrane 
was also probed for PAK1 as a loading and 
siRNA-speciﬁ  city control. (D) Percent increase 
in ﬁ  brinogen binding to siRNA-treated mega-
karyocytes stimulated with 1 and 6 mM PAR4P. 
The P value of murine (m) CIB1 siRNA–treated 
megakaryocytes was compared with untrans-
fected (untr) or human CIB1 siRNA control cells 
(ctrl siRNA) at 1 and 6 mM PAR4P. All data 
represent means ± SEM (≥3). *, P < 0.02; 
**, P < 0.04.T
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comparable in megakaryocytes expressing CIB1 F173A-EGFP 
versus CIB1-EGFP (Fig. S1, B and D). These data suggest that 
a direct interaction between CIB1 and the αIIb tail is critical for 
suppression of αIIbβ3 activation.
To further determine whether CIB1 suppresses integrin acti-
vation by a direct or indirect mechanism, we tested its ability 
to suppress activation of αV integrins because we previously 
determined that CIB1 does not interact with the αV cytoplasmic 
tail (Naik et al., 1997; Barry et al., 2002) and because mega-
karyocytes express the αV integrin subunit (Fig. S3 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200505131/DC1). 
We found that neither CIB1-EGFP nor CIB1 F173A-EGFP had 
an effect on αV integrin activation as detected with WOW-1, a 
mAb that selectively recognizes activated αVβ3 and to a lesser 
extent, activated αVβ5 (Pampori et al., 1999), compared with 
untransduced megakaryocytes or megakaryocytes expressing 
EGFP alone (Fig. S3 B). These results suggest that CIB1 selec-
tively inhibits the activation of αIIbβ3, most likely via a direct 
interaction with the integrin.
To determine the role of endogenous CIB1 in agonist-
 induced  αIIbβ3 activation, we reduced CIB1 levels by RNA 
interference. Introduction of murine CIB1–specifi  c small inter-
fering RNAs (siRNAs) into megakaryocytes resulted in a consis-
tent knockdown of endogenous CIB1 protein levels by 40–60% 
(Fig. 1 C). We observed a statistically signifi  cant increase in 
fi  brinogen binding to megakaryocytes with reduced CIB1 ex-
pression, relative to cells transfected with a human CIB1 siRNA 
control or untransfected cells, at two different concentrations of 
PAR4P (Fig. 1 D). This increased fi  brinogen binding was not 
attributable to changes in αIIb expression because fl  ow cyto-
metric data indicated comparable expression levels of αIIbβ3 
integrin in all transfected groups (Fig. S3 C). Moreover, no en-
hancement of basal fi  brinogen binding in the absence of agonist 
was observed in CIB1-depleted cells (Fig. S3 D). Thus, a con-
sistent correlation was observed between reduced CIB1 expres-
sion and increased fi   brinogen binding to agonist-stimulated 
megakaryocytes. These data therefore complement the CIB1 
overexpression studies and indicate a negative regulatory role 
for CIB1 in αIIbβ3 activation.
Our data showing that CIB1 is an endogenous inhibitor 
of αIIbβ3 activation are in apparent contradiction to a study 
showing that CIB1 activates αIIbβ3 (Tsuboi, 2002). In this 
study, a CIB1 peptide introduced into platelets blocked agonist-
induced αIIbβ3 activation. It was proposed that this blockage 
occurred because the peptide displaced endogenous CIB1 from 
αIIb, implying that CIB1 activates αIIbβ3. However, this study 
did not show a direct interaction between the CIB1 peptide 
and αIIb. Moreover, these results may be interpreted as an 
  ability of this peptide to bind αIIb and mimic the inhibitory 
function of intact CIB1.
We next examined the localization of CIB1 and αIIbβ3 in 
resting and activated megakaryocytes by immunofl  uorescence. 
Confocal images of nonstimulated megakaryocytes showed 
CIB1 colocalizing with αIIb at the cell periphery (Fig. 2 A, left 
and inset). Upon agonist stimulation (PAR4P) in the absence 
of added fi  brinogen, we observed a potential increase in mem-
brane colocalization of CIB1 with αIIb (Fig. 2 A, middle and 
inset) that did not reach statistical signifi  cance (Fig. 2 B). How-
ever, this trend is in agreement with our coimmunoprecipitation 
experiments (Fig. 1 A) and Vallar et al. (1999). In contrast, 
upon agonist stimulation in the presence of soluble fi  brinogen, 
CIB1 colocalization with αIIb decreased considerably (Fig. 2 B), 
as shown by distinct areas of nonoverlapping staining of 
CIB1 and αIIb (Fig. 2 A, right and inset), suggesting a loss of 
the CIB1–αIIb interaction upon ligand occupancy of αIIbβ3. 
These results suggest that the CIB1–αIIb interaction is dynami-
cally and spatially regulated by agonist stimulation and ligand 
occupancy. In addition to the effects of CIB1 on inside-out sig-
naling, the signifi  cant redistribution of CIB1 upon fi  brinogen 
binding to activated αIIbβ3 suggests that CIB1 may also be-
come available to mediate outside-in signaling events. In this 
regard, it has been reported that CIB1 contributes to outside-in 
signaling via αIIbβ3 (Naik and Naik, 2003b).
To determine a molecular mechanism by which CIB1 
inhibits  αIIbβ3 activation, we asked whether CIB1 affects 
binding of the integrin-activating protein talin with both the 
Figure 2.  Colocalization of endogenous CIB1 and 𝗂IIb𝗃3 in nonstimulated 
and agonist-stimulated megakaryocytes.  (A) Nonstimulated, PAR4P, or 
PAR4P + ﬁ  brinogen (Fg)–treated megakaryocytes were adhered to poly-L-
  lysine, ﬁ  xed, and stained with antibodies against CIB1 and αIIb. CIB1 is 
shown in green, αIIb in red, and colocalization in yellow. Boxed areas are 
enlarged to show membrane distribution of CIB1 and αIIb. Bars, 20 μm. 
(B) Histogram depicts relative colocalization R values calculated as described 
in Materials and methods. *, P < 0.01, as compared with agonist-stimulated 
conditions. Data represent means ± SEM (n = 4) for each condition.JCB • VOLUME 172 • NUMBER 2 • 2006  172
αIIb cytoplasmic tail and the intact integrin heterodimer. 
Talin is a cytoskeletal protein recently shown to play a critical 
role in activating several integrins via interaction of the talin 
head domain (THD) with β cytoplasmic tails, including β3 
 (Calderwood et al., 1999; Tadokoro et al., 2003); in addition, talin 
also binds to the αIIb cytoplasmic tail (Knezevic et al., 1996). 
Using recombinant CIB1 and THD in solid-phase binding as-
says, we found that both CIB1 and THD bound to immobilized 
αIIb cytoplasmic tail peptide in a direct, saturable manner 
(Fig. 3, A and B), with THD binding to immobilized αIIb pep-
tide at a slightly higher apparent affi  nity. To determine rela-
tive affi  nities of CIB1 and THD for soluble versus immobilized 
Figure 3.  CIB1 inhibits talin binding to the 𝗂IIb cytoplasmic tail and 𝗂IIb𝗃3. (A and B) Solid-phase binding studies using recombinant CIB1 and THD. 
  Increasing concentrations of CIB1 (A) or THD (B) were added to wells coated with αIIb cytoplasmic tail peptide. CIB1 or THD binding was detected using an 
anti-CIB1 or anti-talin antibody, respectively. (C) Increasing concentrations of αIIb cytoplasmic tail peptide were incubated with a constant concentration of 
10 nM CIB1 or THD before addition to αIIb peptide-coated wells. Binding of CIB1 or THD was detected as in A and B, respectively. (D) Competitive inhibition 
of THD binding to immobilized αIIb cytoplasmic tail peptide by CIB1. 10 nM of soluble THD was added to wells in the presence of increasing concentrations 
of soluble CIB1. THD binding was detected using an anti-THD rabbit pAb. (E) Competitive inhibition of 10 nM CIB1 binding to immobilized αIIb cytoplasmic 
tail peptide by increasing concentrations of THD. CIB1 binding was detected using a chicken anti-CIB1 antibody. (F) CIB1 partially inhibits αIIbβ3 binding 
to immobilized THD. Soluble, activated RGD afﬁ  nity–puriﬁ  ed αIIbβ3 (Frelinger et al., 1990) was incubated with increasing concentrations of CIB1 or CIB1 
F173A before addition to immobilized THD. Integrin αIIbβ3 binding was detected using an anti-αIIb mAb. Data represent means ± SEM (≥3).CIB1 INHIBITS αIIBβ3 ACTIVATION • YUAN ET AL. 173
αIIb tail, equimolar concentrations of soluble CIB1 and THD 
were incubated with increasing concentrations of soluble αIIb 
cytoplasmic tail peptide before addition to immobilized αIIb 
cytoplasmic tail peptide (Fig. 3 C). Although CIB1 binding was 
signifi  cantly inhibited at concentrations of <1 μg of soluble 
peptide per well, no inhibition of THD binding to immobilized 
αIIb cytoplasmic tail peptide was observed at these concentra-
tions, suggesting that CIB1 has a higher relative affi  nity than 
THD for soluble αIIb. These results also suggest that THD has 
a higher relative affi  nity than CIB1 for the immobilized αIIb tail 
peptide. Furthermore, competitive binding assays showed that 
increasing concentrations of soluble CIB1 almost completely 
inhibited THD binding to immobilized αIIb cytoplasmic tail 
peptide (Fig. 3 D). Similarly, soluble THD inhibited CIB1 bind-
ing to immobilized αIIb cytoplasmic tail peptide (Fig. 3 E). 
Consistent with THD having a higher affi  nity for immobilized 
αIIb cytoplasmic tail peptide,  25 nM THD inhibited 50% of 
CIB1 binding to αIIb cytoplasmic tail peptide, whereas this 
concentration of CIB1 had little effect on THD binding to αIIb 
cytoplasmic tail peptide. 
We then asked whether CIB1 interferes with THD bind-
ing to purifi  ed, activated αIIbβ3 heterodimer; CIB1 maximally 
inhibited  50% of the binding of solution phase αIIbβ3 to 
immobilized THD (Fig. 3 F) because higher concentrations of 
CIB1 had no further inhibitory effect (unpublished data). These 
data are consistent with a study showing that an anti–αIIb tail 
antibody also maximally inhibits  50% of αIIbβ3 binding to 
immobilized talin, with the remaining binding attributed to the 
β3 tail (Knezevic et al., 1996). Moreover, the mutant protein 
CIB1 F173A, which does not bind the αIIb tail, did not inhibit 
αIIbβ3 binding to immobilized THD (Fig. 3 F). These results 
suggest that CIB1 inhibits αΙΙbβ3 activation at least in part by 
competing with talin for direct binding to the αIIb cytoplas-
mic tail in platelets and megakaryocytes. These data may also 
indicate that CIB1 prevents a functional engagement of talin 
with αIIbβ3 via a CIB1-associated conformational change in 
αIIb that directly affects β3 so that bound talin cannot activate 
αIIbβ3. The fi  nding that CIB1 overexpression completely in-
hibits αIIbβ3 activation but only partially inhibits talin interac-
tion with αIIbβ3 also raises the possibility that talin binding to 
β3 alone is insuffi  cient to activate αIIbβ3.
Our data demonstrate that CIB1 is an endogenous inhibi-
tor of agonist-induced αIIbβ3 activation. We propose that in the 
resting state, CIB1 is associated with a portion of αIIbβ3 mole-
cules (Fig. 4 A). Agonist stimulation promotes talin association 
with the majority of integrin cytoplasmic tails (Tadokoro et al., 
2003; Calderwood, 2004; Qin et al., 2004; Xiao et al., 2004), 
resulting in αIIbβ3 activation and fi  brinogen binding (Fig. 4 B). 
However, we also predict that during agonist-induced activa-
tion, talin cannot bind to αIIb and/or properly engage β3 within 
the CIB1-associated αIIbβ3 molecules (Fig. 4 C). The numbers 
of CIB1-associated complexes may increase during agonist-
induced activation based on our coimmunoprecipitation data 
(Fig. 1 A) and the observed trend toward increased colocaliza-
tion (Fig. 2), thus implicating a role for CIB1 during inside-
out signaling events that regulate integrin αIIbβ3 activation. 
Consequently, this portion of CIB1-occupied αIIbβ3 would 
be unable to undergo agonist-induced activation and fi  brino-
gen binding (Fig. 4 C). Furthermore, the redistribution upon 
soluble fi  brinogen binding (Fig. 2) and decreased relative colo-
calization of CIB1 with αIIbβ3 suggests that CIB1 may also be 
regulated by and participate in outside-in signaling via αIIbβ3. 
Because a decrease in endogenous CIB1 levels does not induce 
spontaneous integrin activation (Fig. S3 D), our model further 
predicts that CIB1 exerts its effect on αIIbβ3 during agonist 
stimulation to limit the extent of activation, as opposed to main-
taining αIIbβ3 in a resting state in unstimulated cells, which 
may instead be regulated by properties intrinsic to the integrin 
(O’Toole et al., 1990).
In conclusion, our results indicate that CIB1 is a negative 
regulator of agonist-induced αIIbβ3 activation, thus providing a 
mechanism for the precise control of αIIbβ3 activation in mega-
karyocytes. Although megakaryocytes are not platelets, they 
are platelet precursors and share many similarities, suggesting 
that the function of CIB1 extends to platelets. It will be of in-
terest in future studies to determine whether endogenous CIB1 
levels in platelets correlate inversely with platelet reactivity, 
a known risk factor for coronary artery disease (Frenkel and 
Mammen, 2003).
Materials and methods
Megakaryocyte transfection and ﬂ  ow cytometry
The Sindbis expression system was obtained from Invitrogen. The human 
CIB1 gene or a mutant human CIB1 gene (F173A; Barry et al., 2002) was 
fused to the EGFP gene at the COOH terminus of CIB1 and cloned into the 
pSinRep5 vector. The virus was produced in BHK cells for megakaryocyte 
transduction. Megakaryocytes were derived from bone marrow cultures of 
Figure 4.  Model of CIB1 regulation of 𝗂IIb𝗃3 activation. (A) In the resting 
state, a limited amount of CIB1 may be associated with a portion of resting 
αIIbβ3. (B) Upon agonist stimulation, most αIIbβ3 molecules are predicted 
to become associated with talin, which converts αIIbβ3 to an activated 
state such that the integrin can bind ﬁ  brinogen (Fg). (C) Agonist stimulation 
may induce a redistribution of additional CIB1 to the plasma membrane to 
facilitate further association of CIB1 with a portion of αIIbβ3 molecules via 
binding to the αIIb tail. CIB1-associated αIIbβ3 is unable to bind talin in a 
fully functional manner and therefore remains in a resting or intermediate 
state unable to bind ﬁ  brinogen.JCB • VOLUME 172 • NUMBER 2 • 2006  174
C57BL/6J mice, and ﬂ  ow cytometry was performed as described previously 
(Shiraga et al., 1999). Differentiated megakaryocytes were transduced with 
various viral constructs for 20 h and collected in modiﬁ  ed Tyrode’s buffer with 
1 mM CaCl2 and 1 mM MgCl2 (Shiraga et al., 1999) at 10
6 cells/ml. Over-
expression level of CIB1-EGFP and CIB1 F173A-EGFP were quantiﬁ  ed via 
densitometry using the software Quantity One (Fluor-S Multimager; Bio-Rad 
Laboratories) and adjusted as fold over endogenous CIB1 expression. 
50 μl of the megakaryocyte suspension was mixed with agonist PAR4P 
(GYPGKF) and soluble Alexa Fluor 546–conjugated ﬁ  brinogen (15 μg/ml 
ﬁ  nal concentration; Invitrogen) at RT for 30 min and diluted with chilled 
  Tyrode’s buffer containing propidium iodide at a ﬁ  nal concentration of 
1 μg/ml. Cells were immediately analyzed on a ﬂ  ow cytometer (FACStar 
Plus; Becton Dickinson). Live, EGFP-positive megakaryocytes were mea-
sured for Alexa Fluor 546 ﬁ  brinogen binding in the FL2 channel. Data 
were collected as mean ﬂ   uorescence intensities using Summit software 
(DakoCytomation). Basal ﬁ  brinogen binding is deﬁ  ned as the mean ﬂ  uo-
rescence intensity of megakaryocytes with Alexa Fluor 546 ﬁ  brinogen but 
without agonist stimulation. The t test was used in statistical analyses in 
all experiments.
siRNA construction and transfection
Murine CIB1–speciﬁ   c siRNAs were generated with the Silencer siRNA 
construction kit (Ambion; Elbashir et al., 2002). Two 21-base sequences 
were developed that target sites (208) 5′-AAGGAGCGAAUCUGCAUG-
GUC-3′ and (448) 5′-AAGCAGCUGAUUGACAAUAUC-3′ of the mRNA 
transcript as well as a control human CIB1–speciﬁ  c siRNA (5′- A  A  G  U  G    -
C  C  C  U  U  C  G  A  G  C  A  G  A  U  U  C  -3′), which has no homology to murine CIB1 
or to any sequence in the mouse genome. Megakaryocytes were trans-
duced with siRNAs at 200 nM (according to the manufacturer’s protocol; 
Mirus), incubated at 37°C for 48 h, and subjected to ﬂ  ow cytometry and 
Western blotting.
Solid-phase binding assays
Microtiter wells (Immulon 2 HB; Dynex Technologies) were coated with 
and without 5 μg/well of full-length human αIIb cytoplasmic tail peptide 
(L  V  L  A  M  W  K  V  G  F  F  K  R  N  R  P  P  L  E  E  D  D  E  E  G  Q  ) or 2.5 μg/well of puriﬁ  ed THD and 
blocked with 3% BSA. CIB1 or THD (50 μl) were incubated for 1 h, and 
binding was detected with a chicken anti-CIB1 polyclonal antibody (pAb) 
or mouse anti-talin (clone 8d4; Sigma-Aldrich). For competition binding 
assays, 10 nM of soluble CIB1 or THD was incubated with increasing con-
centrations of soluble αIIb cytoplasmic tail peptide, THD, or CIB1 before ad-
dition to wells containing immobilized αIIb peptide. Binding of CIB1 or THD 
was detected using an anti-CIB1 or -talin antibody, respectively. Binding of 
RGD-puriﬁ  ed αIIbβ3 (Frelinger et al., 1990) to immobilized THD ± CIB1 or 
CIB1 F173A proceeded for 2–3 h. Integrin αIIbβ3 binding was detected 
with a mAb, 11G1, which recognizes the intracellular portion of αIIb and 
does not overlap with the CIB1 binding site.
Immunoﬂ  uorescence
Cultured murine megakaryocytes on poly-L-lysine were stained with anti-
bodies against CIB1 and αIIb. CIB1 localization was detected with a 
chick pAb, and αIIb was recognized by rabbit anti-αIIb pAb. Confocal 
images were captured by Fluoview software (Olympus) with a Fluoview 300 
laser   scanning confocal imaging system conﬁ   gured with a ﬂ  uorescence 
microscope (Olympus; IX70) ﬁ  tted with a Plan Apo 60× oil objective. The 
images were assembled (Fig. 2) in Photoshop 7.0 (Adobe). To quantify 
the relative colocalization of multiple images (n = 4), we calculated the 
RColoc value (Pearson’s correlation coefﬁ  cients, per image set, for pixels 
above the calculated thresholds for the images). Pearson coefﬁ  cient is a 
statistical appraisal of how well a linear equation describes the relation-
ship between two variables for a measured function and is commonly used 
in image colocalization analysis.
Online supplemental material
Fig. S1 characterizes the overexpression of wild-type CIB1 and mutant CIB1 
F173A and the ﬁ   brinogen binding to megakaryocytes expressing these 
  fusion proteins. Fig. S2 shows the binding characteristics of wild-type CIB1 
and mutant CIB1 F173A to PAK1 and integrin αIIb. Fig. S3 shows integrin αV 
expression and activation and also shows effects of CIB1 depletion on inte-
grin αIIbβ3 expression and basal activation. Online supplemental material 
is available at http://www.jcb.org/cgi/content/full/jcb.200505131/DC1.
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